. 2018 Nov 19;2018:3947626. doi: 10.1155/2018/3947626

Table 2.

Characteristics of eligible studies included in this meta-analysis.

Number	Study	Year	Country	Ethnicity	Number of patients	Age	Cancer types	Chemotherapeutic	TNM stage	Evaluation criterion	Outcomes	ERCC2 rs13181				ERCC2 rs1799793
Number	Study	Year	Country	Ethnicity	Number of patients	Age	Cancer types	Chemotherapeutic	TNM stage	Evaluation criterion	Outcomes	AA	AC	CC	AC + CC	GG	GA	AA	GA + AA
1	Zheng	2016	China	Asia	224	57.4 ± 9.20	Gastric cancer	Platinum-based chemotherapy	I-IV	WHO	ORR	77/39^a	51/33^a	14/10^a	_	82/42^a	46/30^a	14/10^a	_
2	Mo	2015	China	Asia	228	56.65 ± 11.52	Gastric cancer	Platinum-based chemotherapy oxaliplatin	I-IV	RECIST	ORR	82/34^a	54/29^a	17/12^a	71/41^a	87/38^a	56/29^a	10/8^a	66/37^a
3	Yu	2015	China	Asia	346	64.5 ± 9.2	Gastric cancer	Fluorouracil (5FU) and folinic acid chemotherapy	NR	WHO	ORR	141/107^a	_	_	66/32^a	88/79^a	_	_	119/60^a
4	Zhong	2015	China	Asia	263	62.40 ± 9.50	Gastric cancer	FOLFOX chemotherapy	I-IV	WHO	ORR	_	_	_	_	86/57^a	57/45^a	9/9^a	66/54^a
5	Ding	2015	China	Asia	380	58.7 ± 16.3	Gastric cancer	Platinum-based chemotherapy	I-IV	WHO	ORR	92/67^a	_	_	131/90^a	86/79^a	_	_	137/78^a
7	Xue	2015	China	Asia	410	63.7 ± 11.4	Gastric cancer	FOLFOX chemotherapy	I-IV	WHO	ORR	89/69^a	123/52^a	57/20^a	_	108/66^a	123/65^a	37/11^a	_
8	Yu	2015	China	Asia	228	55.7 ± 13.8	Gastric cancer	FOLFOX chemotherapy	I-IV	WHO	ORR	86/50^a	46/32^a	7/7^a	_	79/42^a	54/38^a	6/9^a	_
9	Zhou	2014	China	Asia	415	56.2 ± 15.6	Gastric cancer	Platinum-based chemotherapy	I-IV	WHO	ORR	139/109^a	74/52^a	25/16^a	_	130/119^a	67/46^a	41/12^a	_
11	Goekkurt	2009	Germany	Caucasian	156	64 (27–86)	Gastric cancer	FU and platinum-based	NR	WHO	ORR	66/91^a	60/90^a	36/88^a	_	70/82^a	48/123^a	60/60^a	_
12	Keam	2008	South Korea	Asia	73	59 (24–77)	Gastric cancer	FOLFOX chemotherapy	NR	WHO	ORR	28/4^a	_	_	34/7^a	1/7^a	31/34^a	_	_
13	Ruzzo	2006	Italy	Caucasian	175	61 (38–79)	Gastric cancer	Fluorouracil/cisplatin palliative chemotherapy	I-IV	RECIST	ORR	17/37^a	36/54^a	17/14^a	_	13/34^a	36/52^a	21/19^a	_

NR: not reported; ORR: objective response rate; OS: overall survival; RECIST: Response Evaluation Criteria in Solid Tumors; WHO: World Health Organization; ^anumber of patients for ORR; in front of oblique line is responders (complete response (CR) + partial response (PR)) and behind oblique line is nonresponder (stable disease (SD) + progressive disease (PD)).